This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
CAR-T is a potent and helpful option for many blood cancer patients, but Medicare and Medical insurance coverage can be an obstacle to care. The CLL Society united with other blood cancer organizations to petition CMS to arrange for appropriate payment so that all may have the opportunity to benefit from this breakthrough therapy. Here is the letter we sent.